BV100

Indicaton

Addressing with a pathogen focused approach Gram-negative hospital acquired infections caused by Acinetobacter baumannii.

Therapeutic indications

Infectious disease

Type of product

Small molecule

Table

Phase

Phase I completed
Partnering status

Not partnered
Available in

Global

You may also be interested in

OligoPhore / SemaPhore Peptide-Based RNA Delivery Platforms

Delivers siRNA, antisense oligonucleotides, mRNA and other mRNA modalities to extrahepatic tissues - demonstrated across various indications in oncology (e.g. PDAC, breast cancer, ovarian cancer, lung cancer, melanoma, ATLL, TME), and inflammatory / autoimmune diseases (e.g. OA, RA, enterocolitis), CV (e.g. atherosclerosis, aortic aneurysm)

Discovery

Regkirona (regdanvimab)

Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19

Marketed

Cadazolid

Crohn's disease

Phase II started